Diagnostic Ultrasound Corp. changes name to Verathon

At 25 weeks, FACT-P total score remained comparable between the arms.

Panelists discuss how managing overactive bladder in older adults requires a holistic approach that integrates treatment of comorbidities, emerging therapeutic options, and quality-of-life considerations to optimize patient outcomes.

"The three-year durability data from this study further validate the potential of JELMYTO in providing long-term disease control for patients with low-grade upper tract urothelial cancer,” says Solomon L. Woldu, MD.

Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.

The median time to correct treatment was 98 days with initial TURBT vs 53 days with initial mpMRI.

Ashish M. Kamat, MD, MBBS, provides expert insights into the current state of bladder cancer care, emphasizing the critical role of patient-centric approaches and exploring the evolving treatment landscape. Kamat is an endowed professor of urologic oncology and cancer research at the University of Texas MD Anderson Cancer Center and president of the IBCG (International Bladder Cancer Group) and former president of the IBCN (International Bladder Cancer Network). Dr. Kamat has been compensated by J&J for his time to develop this content.